| PI3K inhibitors are finally coming of age B Vanhaesebroeck, MWD Perry, JR Brown, F André, K Okkenhaug Nature reviews Drug discovery 20 (10), 741-769, 2021 | 311 | 2021 |
| Monocarboxylate transporter MCT1 is a target for immunosuppression CM Murray, R Hutchinson, JR Bantick, GP Belfield, AD Benjamin, ... Nature chemical biology 1 (7), 371-376, 2005 | 289 | 2005 |
| Designing novel building blocks is an overlooked strategy to improve compound quality FW Goldberg, JG Kettle, T Kogej, MWD Perry, NP Tomkinson Drug Discovery Today 20 (1), 11-17, 2015 | 207 | 2015 |
| Structural and conformational determinants of macrocycle cell permeability B Over, P Matsson, C Tyrchan, P Artursson, BC Doak, MA Foley, ... Nature Chemical Biology 12 (12), 1065-1074, 2016 | 185 | 2016 |
| Stabilization of protein-protein interactions in drug discovery SA Andrei, E Sijbesma, M Hann, J Davis, G O’Mahony, MWD Perry, ... Expert opinion on drug discovery 12 (9), 925-940, 2017 | 160 | 2017 |
| Asynchronously calibrated quantitative bone densitometry JK Brown, W Timm, G Bodeen, A Chason, M Perry, F Vernacchia, ... Journal of Clinical Densitometry 20 (2), 216-225, 2017 | 117 | 2017 |
| Compounds J Bantick, M Cooper, P Thorne, M Perry US Patent 6,342,601, 2002 | 104* | 2002 |
| Impact of stereospecific intramolecular hydrogen bonding on cell permeability and physicochemical properties B Over, P McCarren, P Artursson, M Foley, F Giordanetto, G Grönberg, ... Journal of medicinal chemistry 57 (6), 2746-2754, 2014 | 90 | 2014 |
| Evolution of PI3Kγ and δ inhibitors for inflammatory and autoimmune diseases MWD Perry, R Abdulai, M Mogemark, J Petersen, MJ Thomas, B Valastro, ... Journal of Medicinal Chemistry 62 (10), 4783-4814, 2018 | 72 | 2018 |
| Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds SD Guile, JR Bantick, DR Cheshire, ME Cooper, AM Davis, DK Donald, ... Bioorganic & medicinal chemistry letters 16 (8), 2260-2265, 2006 | 70 | 2006 |
| 14-3-3 modulation of the inflammatory response CC Munier, C Ottmann, MWD Perry Pharmacological research 163, 105236, 2021 | 63 | 2021 |
| Synthetic FKBP12 ligands. Design and synthesis of pyranose replacements. TN Birkenshaw, MV Caffrey, DE Cladingboel, ME Cooper, DK Donald, ... Bioorganic & Medicinal Chemistry Letters 4 (21), 2501-2506, 1994 | 60 | 1994 |
| Azo anions in systhesis. pt 1. t-butylhydrazones as acyl-anion equivalents JE Baldwin, RM Adlington, JC Bottaro, JN Kolhe, MWD Perry, AU Jain Tetrahedron 42 (15), 4223-4234, 1986 | 57 | 1986 |
| Design, synthesis, and biological evaluation of MEK PROTACs S Vollmer, D Cunoosamy, H Lv, H Feng, X Li, Z Nan, W Yang, MWD Perry Journal of Medicinal Chemistry 63 (1), 157-162, 2019 | 49 | 2019 |
| A class of highly selective inhibitors bind to an active state of PI3Kγ G Gangadhara, G Dahl, T Bohnacker, R Rae, J Gunnarsson, S Blaho, ... Nature chemical biology 15 (4), 348-357, 2019 | 49 | 2019 |
| Stereocontrol during the alkylation of enolates attached to. pi.-allyl-Mo (CO) 2Cp systems AJ Pearson, S Mallik, R Mortezaei, MWD Perry, RJ Shively Jr, WJ Youngs Journal of the American Chemical Society 112 (22), 8034-8042, 1990 | 47 | 1990 |
| Azo anions in synthesis: Use of trityl-and diphenyl-4-pyridylmethylhydrazones for reductive CC bond formation JE Baldwin, RM Adlington, JC Bottaro, JN Kolhe, IM Newington, ... Tetrahedron 42 (15), 4235-4246, 1986 | 47 | 1986 |
| A Practical Method for Targeted Library Design Balancing Lead‐like Properties with Diversity MJ Stocks, GRH Wilden, G Pairaudeau, MWD Perry, J Steele, ... ChemMedChem: Chemistry Enabling Drug Discovery 4 (5), 800-808, 2009 | 46 | 2009 |
| Compounds D Cheshire, A Cooke, M Cooper, D Donald, M Furber, M Perry, P Thorne US Patent 6,180,635, 2001 | 46 | 2001 |
| Applications of the thermal ene reaction of aldehyde t-butyl-and phenyl-hydrazones JE Baldwin, RM Adlington, AU Jain, JN Kolhe, MWD Perry Tetrahedron 42 (15), 4247-4252, 1986 | 46 | 1986 |
